Eli Lilly Poised to Nab First to Market Advantage with it’s IL-23 Inhibitor Mirikizumab in Ulcerative Colitis, Creating an Opportunity to Build a Loyal Base Ahead of AbbVie and Janssen’s Respective IL-23 Entries, According to Spherix Global Insights
Gastroenterologists project mirikizumab will play a significant role in the treatment of ulcerative colitis Exton, PA., March 15, 2023 –